The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor

BJU Int. 2005 Jun;95(9):1320-6. doi: 10.1111/j.1464-410X.2005.05526.x.

Authors

Joanne Edwards¹, John M S Bartlett

Affiliation

¹ Section of Surgical and Translational Research, Division of Cancer and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow, Scotland, UK. je10b@clinmed.gla.ac.uk

PMID: 15892825
DOI: 10.1111/j.1464-410X.2005.05526.x

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents, Hormonal / therapeutic use*
Drug Resistance, Neoplasm / physiology*
Humans
Male
Mitogen-Activated Protein Kinases / metabolism
Phosphorylation
Prostate-Specific Antigen / metabolism
Prostatic Neoplasms / drug therapy
Prostatic Neoplasms / metabolism*
Protein Serine-Threonine Kinases / metabolism
Proto-Oncogene Proteins / metabolism
Proto-Oncogene Proteins c-akt
Receptors, Androgen / genetics
Receptors, Androgen / metabolism*
Signal Transduction / physiology*
Survival Analysis
Testosterone / physiology

Substances

Antineoplastic Agents, Hormonal
Proto-Oncogene Proteins
Receptors, Androgen
Testosterone
Protein Serine-Threonine Kinases
Proto-Oncogene Proteins c-akt
Mitogen-Activated Protein Kinases
Prostate-Specific Antigen